Genetically Modified Bioprosthetic Heart Valve
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioprosthetic heart valves face issues such as calcification, structural incompatibility, and immune rejection due to either solely decellularization or molecular modification processes.
Innovation Solution
A method involving molecular modification of animal-based heart valves followed by decellularization, targeting specific cells and genes to alter structural and mechanical properties, thereby reducing calcification and immune rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If only decellularization is carried out, then immune rejection is reduced, but calcification and structural incompatibility occur
Solution Approach 1:
Molecular modification is performed as a preliminary action before decellularization to prevent calcification and improve structural integrity. The patent applies genetic modification to the animal-based heart valve tissue prior to the decellularization process, so that the tissue is pre-conditioned to resist calcification and maintain structural compatibility after decellularization.
2Reliability
If only molecular modification is carried out, then structural integrity is improved, but non-human pathogens are introduced and immune response increases
Solution Approach 1:
The patent combines molecular modification and decellularization into a sequential two-step process. Molecular modification is applied first to improve structural integrity, followed by decellularization to remove cellular material that could trigger immune responses. This merging of processes allows both benefits to be achieved while mitigating the drawbacks of each individual approach.
3Reliability
If molecular modification is applied to animal-based heart valves, then calcification is reduced, but process complexity increases
Solution Approach 1:
Molecular modification is performed as a preliminary step before decellularization to prevent calcification. By addressing the calcification issue in advance through genetic modification of the animal tissue, the patent reduces the need for complex post-processing treatments and simplifies the overall production workflow.
Data Source
AI summary
A genetically modified bioprosthetic heart valve and a production method thereof are provided. The production method includes two critical steps for the invention to achieve its related objectives. These criteria are the molecular modification step and subsequent decellularization of animal-based heart valve in valve culture, where the molecular modification step involves an electroporation system and siRNA molecules.